Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Verona
Clinical trial register · Italy

Clinical Trials in Verona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universita di Verona20 Azienda Ospedaliera Universitaria Integrata Verona13 Amgen10 Bristol-Myers Squibb10 AstraZeneca10
Site location
Milan2843 Bologna1305 Roma1274 Naples984 Rome967
All 489 locations
Target enrolment
to

Trials with a site in Verona

277 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Bristol-Myers Squibb
Phase 3
850
Meldola, Candiolo, Bergamo, Brescia, Milan, Pavia, Verona
2026-09-30
Not yet open
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Observational
90
Ancona, Florence, Genova, Messina, Milan, Roma, Rome, Verona
2026-09-15
Not yet open
Universita di Verona
Not applicable
1,614
Verona
2026-09-01
Not yet open
IRCCS San Raffaele
Not applicable
192
Milan, Verona
2026-09-01
Not yet open
Eli Lilly and Company
Phase 3
170
Ancona, Florence, Genova, Messina, Milan, Naples, Verona
2026-09
Recruiting
Boehringer Ingelheim
Phase 3
390
Bari, Florence, Milan, Naples, Palermo, Roma, Verona
2026-07-10
Recruiting
Insel Gruppe AG, University Hospital Bern
Phase 3
400
Naples, Verona
2026-07-02
Recruiting
Takeda
Phase 2
92
Bologna, Verona
2026-06-04
Not yet open
NobelZygoma TiUltra Implant System Study
NCT07258940Edentulous Maxilla, Maxillary Bone Loss, Atrophic Maxilla
Nobel Biocare
Not applicable
85
Verona
2026-06-01
Not yet open
Universita di Verona
Not applicable
80
Verona
2026-06
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Meldola, Florence, Padova, Roma, Verona, Novara
2026-05-27
Recruiting
Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer
NCT06026943Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma
Alpha Tau Medical LTD.
Not applicable
15
Verona
2026-05-06
Recruiting
Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations
NCT07761936PARKINSON DISEASE (Disorder), Pain, Pain Management, Parkinson Disease (PD)
Universita di Verona
Phase 3
60
Verona
2026-04-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Rozzano, Orbassano, Verona, Arezzo, Genova, Milan, Roma
2026-04-23
Active, closed
Novo Nordisk A/S
Phase 3
606
Ferrara, Genoa, Pavia, Palermo, Padova, Verona, Bologna, Rozzano (MI)
2026-04-21
Recruiting
Novo Nordisk A/S
Phase 3
400
Udine, Rome, Milan, San Donato Milanese, Verona
2026-04-20
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugsVisugromab·Visugromab RDE
CatalYm GmbH
Phase 2/3
518
Aviano, Brescia, Ferrara, Meldola, Verona
2026-04-16
Recruiting
Novo Nordisk A/S
Phase 3
400
Naples, Modena, Udine, Rome, Milan, San Donato Milanese, Verona
2026-04-13
Recruiting
Alkermes, Inc.
Phase 3
150
Verona
2026-04-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Rome, Verona
2026-04-01
Recruiting
AstraZeneca
Phase 2
43
Brescia, Rozzano, Torino, Verona
2026-03-28
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Verona, Milan, Napoli Campania
2026-03-26
Recruiting
Eisai Inc.
Phase 2
64
Bologna, Pavia, Verona
2026-03-26
Recruiting
Boehringer Ingelheim
Phase 2
132
Ancona, Bari, Bologna, Messina, Milan, Pavia, San Giovanni Rotondo (FG), Verona
2026-03-23
Recruiting
Sanofi
Observational
60
Ancona, Palermo, Verona
2026-03-16
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Milan, Padova, Roma, Tricase, Verona
2026-03-09
Recruiting
Philogen S.p.A.
Phase 1
42
Reggio Emilia, Verona
2026-03-04
Recruiting
Eli Lilly and Company
Phase 3
300
Ancona, Florence, Messina, Naples, Novara, Padova, Verona
2026-02-05
Recruiting
Universita di Verona
Not applicable
70
Verona
2026-02-02
Recruiting
CSL Behring
Phase 2
63
Verona
2026-02-02
Recruiting
CSL Behring
Phase 2
84
Brindisi, Milan, Modena, Monza, Naples, Verona
2026-01-22
Recruiting
Boehringer Ingelheim
Phase 3
400
Bari, Milan, Misterbianco (CT), Naples, Orbassano (TO), Roma, Rozzano (MI), Verona
2026-01-16
Recruiting
Bristol-Myers Squibb
Phase 1
281
Roma, Verona
2026-01-15
Not yet open
Azienda Ospedaliera Universitaria Integrata Verona
Phase 2
35
Verona
2026-01-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Rozzano, Verona
2026-01-13
Recruiting
Novo Nordisk A/S
Phase 3
460
Milan, Novara, Verona, Trieste
2026-01-08
Recruiting
Incyte Corporation
Phase 1
280
Bologna, Milan, Rome, Verona
2026-01-08
Not yet open
RAPIDE: The Feasibility of a Hybrid Care Model
NCT06735404Diabetes Type 2, Heart Failure
Radboud University Medical Center
Not applicable
180
Verona
2026-01
Active, closed
WATCHMAN FLX Pro European Registry
NCT07262255Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
Boston Scientific Corporation
Observational
189
Catania, Milan, Verona
2025-12-17
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Milan, Padova, Pisa, Verona
2025-12-15
Recruiting
AbbVie
Phase 2/3
490
Milan, Monza, Fano, Aviano, Rome, Candiolo, Catania, Verona
2025-12-10
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488Bladder Cancer, Urinary Bladder Neoplasms
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
45
Verona
2025-12-09
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
153
Bologna, Chieti, Florence, Roma, Verona
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Ancona, Candiolo, Meldola, Ravenna, Roma, Verona
2025-11-30
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Milan, Turin, Verona
2025-11-25
Recruiting
Magnus Nilsson
Phase 3
262
Verona
2025-11-05
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Meldola, Rome, Milan, Rozzano, Pisa, Padova, Naples, Verona
2025-10-23
Recruiting
Italian Translation and Validation of the GIDS-PD Scale for Parkinson's Disease
NCT07316751PARKINSON DISEASE (Disorder), Parkinson Disease
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Observational
190
Milan, Padova, Tricase, Verona
2025-10-08
Recruiting
Incyte Corporation
Phase 1
120
Bergamo, Florence, Milan, Verona
2025-10-01
Recruiting
Catholic University of the Sacred Heart
Not applicable
140
Bologna, Milan, Verona
2025-10-01
Recruiting
Pfizer
Phase 3
680
Aviano, Rome, Roma, Florence, Verona, Bergamo, Caserta, Genova
2025-09-29
Recruiting
Sanofi
Phase 3
124
Florence, Milan, Verona
2025-09-26
Recruiting
A New Portable Device for Non-invasive Ventilatory Support
NCT06716502Healthy, Respiratory Disease
Università Vita-Salute San Raffaele
Not applicable
50
Lecce, Milan, Verona
2025-09-17
Recruiting
Emotional Allodynia Questionnaire (AEQ) in Fibromyalgia (PEARL)
NCT07677631Fibromyalgia, Chronic Pain, Nociplastic Pain
University of Bari
Observational
425
Bari, Bologna, Cagliari, Naples, Verona
2025-09-10
Recruiting
Universita di Verona
Not applicable
324
Verona
2025-09-01
Not yet open
Tumor Rupture During Robotic Partial Nephrectomy
NCT07065825Kidney Cancer, Renal Neoplasms
Azienda Ospedaliera Universitaria Integrata Verona
Observational
100
Verona
2025-09
Active, closed
Amgen
Phase 3
350
Bari, Bergamo, Meldola (FC), Milan, Roma, Verona
2025-08-18
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
90
Bologna, Verona
2025-08-12
Recruiting
Sanofi
Phase 3
192
Florence, Milan, Naples, Rome, Orbassano, Palermo, Verona
2025-08-12
Recruiting
GlaxoSmithKline
Phase 3
420
Milan, Bergamo, Genova, Orbassano, Pisa, Siena, Verona
2025-08-11
Recruiting
Bristol-Myers Squibb
Observational
200
Verona
2025-08-05
Recruiting
Amgen
Phase 1
434
Milan, Pisa, Verona
2025-07-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Monserrato, Milan, Naples, Padova, Ravenna, Verona
2025-07-16
Active, closed
Verona Coronary Physiology Interventional Registry
NCT07186582Coronary Artery Disease, Ischemic Heart Disease (IHD), Coronary Heart Disease (CHD)
Azienda Ospedaliera Universitaria Integrata Verona
Observational
1,000
Verona
2025-07-14
Active, closed
Novartis Pharmaceuticals
Phase 2
168
Asti, Padova, Trento, Orbassano, Verona
2025-07-07
Recruiting
Fear of Falling in Muscular Dystrophy
NCT07129954Fear of Falling, Duchenne Muscular Dystrophy (DMD), Muscular Dystrophies, Rehabilitation
Universita di Verona
Not applicable
100
Verona
2025-07-02
Recruiting
Biokosmes Srl
Not applicable
90
Milan, Verona, Voghera
2025-06-05
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Padova, Rome, Verona
2025-05-28
Active, closed
Alkermes, Inc.
Phase 2
126
Bologna, Milan, Verona
2025-05-22
Recruiting
Shockwave™Peripheral Intravascular Lithotripsy Balloon for Advanced Endovascular Aortic Repair
NCT06332911Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture, Abdominal Aortic Aneurysm Without Rupture, Thoracic Aortic Aneurysm Without Rupture
Rede Optimus Hospitalar SA
Observational
30
Genoa, Verona
2025-05-19
Active, closed
Boehringer Ingelheim
Phase 1
91
Meldola (FC), Verona
2025-05-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Milan, Verona, Bologna, Genova, Pavia, Roma, Sassari
2025-05-12
Recruiting
Takeda
Phase 2
88
Rome, Verona, Bologna
2025-05-06
Recruiting
Unmet Needs Among Patients With Isolated REM Sleep Behavior Disorder (iRBD) and Their Significant Others
NCT07498452REM Sleep Behavior Disorder, Isolated REM Sleep Behavior Disorder
Universita di Verona
Observational
150
Bologna, Genoa, Milan, Pavia, Cagliari, Troina, Pisa, Verona
2025-05-06
Recruiting
BioNTech SE
Phase 1/2
594
Candiolo, Milan, Naples, Roma, Verona
2025-05-02
Recruiting
Universita di Verona
Observational
250
Verona
2025-05-01
Recruiting
Universita di Verona
Not applicable
237
Verona
2025-04-09
Recruiting
Self-Help Plus for Distress in University Students
NCT06606249Psychological Distress, Psychological Well-Being, Depression, Anxiety
University of Padova
Not applicable
210
Bari, Padova, Verona
2025-03-10
Recruiting
Universita di Verona
Not applicable
50
Verona
2025-03-10
Recruiting
BeOne Medicines
Phase 3
300
Bologna, Lecce, Meldola, Trieste, Verona
2025-03-05
Not yet open
Gallbladder Stenting in FC-SEMS
NCT06820541Biliary Obstruction, Acute Cholecystitis
Azienda Ospedaliera Universitaria Integrata Verona
Not applicable
80
Verona
2025-03-01
Recruiting
Amgen
Phase 3
844
Udine, Rome, Milan, Turin, Verona, Pisa, Reggio Emilia
2025-02-25
Recruiting
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions
NCT07091682Coronary Artery Disease, Atherosclerosis of Coronary Artery, Myocardial Ischemia, Ischemic Heart Disease
Biotronik AG
Not applicable
100
Milan, Verona
2025-02-18
Recruiting
Novo Nordisk A/S
Phase 3
510
Orbassano, Verona, Brescia, Catania, Modena, Monza, Naples, Padova
2025-02-17
By invitation
Longboard Pharmaceuticals
Phase 3
324
Florence, Genoa, Milan, Pavia, Rome, Verona
2025-02-12
Recruiting
Takeda
Phase 2
96
Pozzilli, Rome, Verona, Bologna
2025-02-07
Recruiting
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugALKS 2680
Alkermes, Inc.
Phase 2/3
256
Bologna, Milan, Verona
2025-01-27
Recruiting
ETOP IBCSG Partners Foundation
Phase 3
290
Alessandria, Padova, Perugia, Rome, Siena, Verona
2025-01-15
Recruiting
Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes
NCT07291609Chronic Coronary Syndrome, Microplastics, Nanoplastics, Coronary Artery Disease
Azienda Ospedaliera "Sant'Andrea"
Observational
120
Caserta, Forlì, Milan, Naples, Roma, Verona
2025-01-01
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
DrugsKeytruda·Pembrolizumab
Alnylam Pharmaceuticals
Phase 1
158
Milan, Rozzano, Verona
2024-12-30
Recruiting
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06752668Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
248
Bologna, Pozzilli, Verona
2024-12-23
Recruiting
Istituto Oncologico Veneto IRCCS
Not applicable
200
Bergamo, Bologna, Foggia, Padova, Palermo, Udine, Verona
2024-12-20
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Ancona, Brescia, Monza, Milan, Rozzano, Verona
2024-12-17
Recruiting
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
170
Milan, Ravenna, Roma, Verona
2024-12-16
Recruiting
The Leeds Teaching Hospitals NHS Trust
Observational
550
Brescia, Catania, Genova, Milan, Palermo, San Donato Milanese, Torino, Verona
2024-12-12
Active, closed
Hoffmann-La Roche
Phase 2
62
Bari, Rome, Orbassano, Verona
2024-12-09
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Milan, Roma, Torino, Verona
2024-12-09
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
160
Bologna, Verona
2024-12
Recruiting
BeOne Medicines
Phase 1/2
80
Bologna, Milan, Naples, Rozzano, Verona
2024-11-27
Recruiting
Eli Lilly and Company
Phase 3
150
Florence, Novara, Verona
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
125
Florence, Modena, Novara, Parma, Roma, Verona
2024-11-18
Recruiting
Genentech, Inc.
Phase 1
410
Verona
2024-11-14
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Florence, Genoa, Milan, Pavia, Rome, Verona
2024-11-11
Active, closed
Metacognitive Interpersonal Therapy Across Transdiagnostic Eating Disorders, Including Underweight
NCT06693089Eating Disorders, Maladaptive Personality Trait, Personality Disorder, Personality Trait
GLORIA FIORAVANTI
Not applicable
64
Verona
2024-11-08
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Verona
2024-10-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Catanzaro, Ravenna, Rome, Milan, Naples, Padova, Verona
2024-10-21
Active, closed
Universita di Verona
Observational
30
Verona
2024-10-17
Active, closed
Uniquity One (UNI)
Phase 2
184
Milan, Campobasso, Padova, Roma, Pieve Emanuele, Verona
2024-10-16
Recruiting
Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study
NCT06826963Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction, Sarcopenia in Elderly, Sarcopenic Obesity
Universita di Verona
Not applicable
15
Verona
2024-10-15
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Ancona, Milan, Rozzano, Modena, Palermo, Pavia, Roma, Verona
2024-10-09
Recruiting
Universita di Verona
Not applicable
416
Verona
2024-10-01
Recruiting
GlaxoSmithKline
Phase 1
845
Milan, Naples, Roma, Verona
2024-09-30
Active, closed
AstraZeneca
Phase 3
310
Florence, Orbassano, Roma, Verona
2024-09-30
Active, closed
Longboard Pharmaceuticals
Phase 3
96
Florence, Genoa, Pavia, Rome, Verona
2024-09-25
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Ferrara, Genova, Milan, Pisa, Roma, Torino, Verona
2024-09-17
Active, closed
Amgen
Phase 1
49
Alessandria, Milan, Rozzano (MI), Verona
2024-09-17
Active, closed
Novo Nordisk A/S
Phase 4
500
Florence, Milan, Roma, Trieste, Verona
2024-09-17
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Cetuximab·Irinotecan·Adrucil
Eli Lilly and Company
Phase 1
630
Naples, Roma, Verona
2024-09-12
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Campania, Milan, Pisa, Rome, Verona
2024-08-31
Active, closed
Università Vita-Salute San Raffaele
Not applicable
100
Milan, Verona
2024-07-29
Recruiting
TRAns-Femoral Access Intravascular Lithotripsy Comparison With PTA in TAVI
NCT05873842Trans-femoral TAVI With Calcified Ilio-femoral Arteries
Rede Optimus Hospitalar SA
Observational
50
Ancona, Mestre, Treviso, Verona, Vicenza
2024-07-22
Recruiting
Bristol-Myers Squibb
Phase 1/2
224
Milan, Padua, Verona
2024-07-17
Active, closed
Celldex Therapeutics
Phase 3
963
Ancona, Mantua, Milan, Naples, Torino, Verona
2024-07-11
Recruiting
ABX advanced biochemical compounds GmbH
Phase 3
380
Meldola, Verona
2024-06-13
Active, closed
Exelixis
Phase 2/3
600
Candiolo, Brescia, Catania, Milan, Naples, Rome, Rozzano, Verona
2024-06-07
Active, closed
Amgen
Phase 3
563
Bari, Milan, Verona
2024-06-05
Active, closed
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
NCT06406387Pancreatic Neuroendocrine Tumor
Azienda Ospedaliera Universitaria Integrata Verona
Observational
100
Verona
2024-06-01
Active, closed
Amgen
Phase 1
120
Milan, Rozzano MI, Verona
2024-05-29
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Naples, Milan, Misterbianco (CT), Verona
2024-05-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Rome, Milan, Rozzano, Verona
2024-05-20
Recruiting
W.L.Gore & Associates
Observational
2,000
Ancona, Bari, Pavia, Torino, Verona
2024-05-07
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
60
Milan, Rozzano, Verona
2024-04-29
Active, closed
Amgen
Phase 3
111
Genova, Verona
2024-04-22
Active, closed
Amgen
Phase 3
434
Reggio Emilia, Udine, Rome, Milan, Novara, Florence, Verona, Catania
2024-04-08
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Florence, Milan, Rome, Verona
2024-04-01
Active, closed
GlaxoSmithKline
Phase 4
336
Genova, Monserrato CA, Naples, Pieve Di Soligo TV, Roma, Rozzano, Verona
2024-03-20
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Bergamo, Genova, Naples, Verona
2024-02-26
Recruiting
Azienda Ospedaliera Universitaria Integrata Verona
Not applicable
30
Verona
2024-02-01
Recruiting
Genexine, Inc.
Phase 3
429
Brescia, Florence, Foggia, Genova, Pavia, Pisa, Verona
2024-01-25
Active, closed
DualityBio Inc.
Phase 3
541
Bergamo, Brescia, Catania, Catanzaro, Milan, Pavia, Verona, Naples
2024-01-18
Recruiting
Incyte Corporation
Phase 1
710
Milan, Rozzano, Verona
2024-01-04
Recruiting
Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling
NCT06356727Heart Failure, Left Ventricular Dysfunction, Idiopathic Dilated Cardiomyopathy
Azienda Ospedaliera Universitaria Integrata Verona
Not applicable
190
Ferrara, Genova, Milan, Naples, Roma, Rome, Torino, Verona
2024-01-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Florence, Milan, Padova, Pisa, San Giovanni Rotondo, Verona
2024-01-03
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Bologna, Brescia, Milan, Pisa, Ravenna, Roma, Verona
2023-12-29
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Bologna, Rome, Verona
2023-12-27
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Milan, Roma, Trento, Verona
2023-12-20
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Meldola, Genova, Milan, Modena, Pavia, Ravenna, Roma, Verona
2023-12-18
Active, closed
Sanofi
Phase 2
197
Torette, Florence, Milan, Naples, Rome, Novara, Varese, Verona
2023-12-11
Recruiting
Sanofi
Observational
230
Bologna, Brescia, Florence, Milan, Naples, Roma, Verona
2023-11-30
Active, closed
Effects of Topical Fluoride in Orthodontic Patients
NCT07091890Topical Fluoride, Orthodontic Patients, Antimicrobial Effect, Clinical Effect
Universita di Verona
Not applicable
60
Verona
2023-11-16
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
Verona, Ancona, Aviano, Meldola, Milan, Naples, Orbassano, Ravenna
2023-11-14
Active, closed
Ipsen
Observational
1,057
Foggia, Lecco, Milan, Novara, Salerno, Verona
2023-11-01
Not yet open
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2
35
Milan, Siena, Verona
2023-11
Recruiting
United Therapeutics
Phase 3
698
Catania, Forlì, Modena, Monza, Roma, Siena, Verona
2023-10-30
Recruiting
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
170
Reggio Emilia, Bari, Meldola, Milan, Roma, Verona
2023-10-27
Recruiting
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsAdagrasib·Cabozantinib
Kura Oncology, Inc.
Phase 1
300
Bologna, Candiolo, Naples, Rozzano, Verona
2023-10-18
Active, closed
Eli Lilly and Company
Phase 3
160
Bologna, Verona, Messina, Novara
2023-10-16
Active, closed
Hoffmann-La Roche
Phase 3
687
Tricase, Bologna, Rome, Genoa, Rozzano, Palermo, Verona
2023-09-14
Recruiting
Hoffmann-La Roche
Phase 3
230
Meldola, Rome, Milan, Monza, Novara, Palermo, Bagno a Ripoli, Verona
2023-09-08
Active, closed
Boehringer Ingelheim
Phase 2
268
Florence, Palermo, Pavia, Rozzano (MI), Verona
2023-09-08
Recruiting
National Cancer Institute, Naples
Phase 2
38
Naples, Roma, Torino, Verona
2023-09-01
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Ferrara, Padova, Pisa, Verona
2023-08-30
Recruiting
Incyte Corporation
Phase 1
570
Milan, Rozzano, Verona
2023-07-24
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Bologna, Rozzano, Verona
2023-07-05
Recruiting
Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation
NCT06820125Rehabilitation, Multiple Sclerosis, Cognitive Deficit, Motor Deficits
Universita di Verona
Not applicable
48
Verona
2023-07-05
Recruiting
Shockwave IVL + DCB
NCT05625997Calcified Lesions in Small Coronary Vessels
Rede Optimus Hospitalar SA
Observational
50
Verona
2023-06-16
Recruiting
National Cancer Institute, Naples
Phase 2
240
Naples, Milan, Roma, Verona
2023-06-12
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
Milan, Orbassano, Verona
2023-05-18
Active, closed
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
DrugTislelizumab
HiFiBiO Therapeutics
Phase 1
83
Naples, Rome, Verona
2023-05-09
Active, closed
Prof. Massimo Filippi
Not applicable
80
Milan, Verona
2023-04-30
Recruiting
ANRS, Emerging Infectious Diseases
Phase 2
256
Verona
2023-04-27
Active, closed
OncoSil Medical Limited
Phase 2
88
Rome, Verona
2023-04-26
Recruiting
Eli Lilly and Company
Phase 1/2
880
Alessandria, Brescia, Milan, Monza, Pisa, Ravenna, Roma, Verona
2023-04-17
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
Schrödinger, Inc.
Phase 1
98
Alessandria, Milan, Torino, Verona
2023-04-10
Active, closed
Novartis Pharmaceuticals
Phase 4
240
Ancona, Torino, Negrar, Verona
2023-03-28
Active, closed
BeiGene
Phase 2
400
Roma, Verona
2023-03-07
Active, closed
Azienda Ospedaliera Universitaria Integrata Verona
Not applicable
60
Verona
2023-03-01
Recruiting
Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis
NCT06964581Telerehabilitation, Multiple Sclerosis, Cognitive Disorders, Neurorehabilitation
Universita di Verona
Not applicable
60
Verona
2023-02-08
Not yet open
Universita di Verona
Phase 2
105
Verona
2023-02-01
Recruiting
Universita di Verona
Not applicable
33
Verona
2023-01-27
Recruiting
Universita di Verona
Not applicable
1,030
Cuneo, Reggio Emilia, Verona
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
516
Rome, Milan, Pisa, Padova, Brescia, Naples, Verona
2023-01-12
Active, closed
Daiichi Sankyo
Phase 3
1,170
Candiolo, Lucca, Orbassano, Rome, Udine, Varese, Verona
2023-01-11
Active, closed
Zenas BioPharma (USA), LLC
Phase 3
194
Turin, Brescia, Florence, Milan, Verona
2023-01-09
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Observational
326
Cremona, Florence, Milan, Abano Terme, Verona, Parma
2022-12-22
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Milan, Orbassano, Rozzano, Verona
2022-12-21
Recruiting
Familial Pancreatic Cancer PROPHilation Program in Italy
NCT05724992Candidates for Hereditary Pancreatic Cancer Testing
Associazione Italiana per lo Studio del Pancreas
Not applicable
3,000
Verona
2022-12-20
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Florence, Naples, Roma, Torino, Trieste, Verona
2022-12-15
Recruiting
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
NCT05845801PDAC - Pancreatic Ductal Adenocarcinoma
Azienda Ospedaliera Universitaria Integrata Verona
Observational
3,000
Verona
2022-12-07
Active, closed
AstraZeneca
Phase 3
368
Bologna, Milan, Naples, Padova, Pisa, Roma, Rozzano, Verona
2022-11-10
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Ancona, Florence, Genova, Milan, Orbassano, Potenza, Verona
2022-11-08
Active, closed
University of Bologna
Observational
240
Padova, Palermo, Varese, Verona
2022-11-01
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
600
Genova, Legnago, Pavia, Treviglio, Verona
2022-10-27
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Milan, Verona, Bologna
2022-10-25
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Monserrato, Avellino, Rome, Tricase, Brescia, Milan, Naples, Verona
2022-10-24
Active, closed
GlaxoSmithKline
Phase 2
351
Avellino, Bergamo, Genova, Pisa, Verona
2022-10-14
Active, closed
Optilume Registry for Treatment of Stricture of the Anterior Urethra
NCT05479422Anterior Urethral Stricture, Male
European Association of Urology Research Foundation
Observational
150
Milan, Torino, Verona
2022-10-13
Active, closed
Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder
NCT05373719Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
Loulou Foundation
Observational
112
Florence, Roma, Rome, Verona
2022-09-30
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugElironrasib
Revolution Medicines, Inc.
Phase 1
222
Milan, Naples, Orbassano, Pavia, Verona
2022-09-19
Active, closed
Redx Pharma Ltd
Phase 2
48
Ancona, Catania, Foggia, Lecce, Milan, Modena, Roma, Verona
2022-09-08
Recruiting
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Observational
429
Bergamo, Milan, Pavia, Varese, Padova, Verona, Vicenza, Alessandria
2022-09-08
Active, closed
Hoffmann-La Roche
Phase 3
132
Pavia, Orbassano, Verona
2022-08-30
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
San Giovanni Rotondo, Meldola, Reggio Emilia, Milan, Candiolo, Pisa, Terni, Verona
2022-08-08
Active, closed
Genentech, Inc.
Phase 3
373
Modena, Rome, Genoa, Milan, Torrette Di Ancona, Verona
2022-08-03
Recruiting
AIOCC Italian Registry on Head and Neck Carcinomas
NCT06248944Head and Neck Carcinoma
Italian Head&Neck Society
Observational
7,000
Candiolo, Florence, Lecce, Milan, Pavia, Roma, Verona
2022-07-06
Active, closed
Incyte Corporation
Phase 1
291
Milan, Naples, Rome, Rozzano, Verona
2022-07-05
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Verona
2022-06-30
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Milan, Rozzano, Verona
2022-06-07
Recruiting
SK Life Science, Inc.
Phase 3
252
Genoa, Milan, Verona, Florence
2022-04-28
Recruiting
Azienda Ospedaliera Universitaria Integrata Verona
Phase 3
98
Verona
2022-03-31
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Florence, Genova, Modena, Roma, Verona
2022-03-08
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Bologna, Rome, Verona
2022-02-21
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 2
310
Naples, Modena, Aviano, Rome, Milan, Verona, Bologna
2022-02-17
Active, closed
UCB Biopharma SRL
Phase 3
113
Pavia, Roma, Verona
2022-02-02
Active, closed
Boston Scientific Corporation
Not applicable
500
Parma, Rome, Verona
2021-12-21
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Milan, Roma, Verona, Novara
2021-12-16
Active, closed
Alnylam Pharmaceuticals
Observational
207
Orbassano, Milan, Verona
2021-12-13
Active, closed
Abivax S.A.
Phase 2
203
Roma, Rozzano, Verona
2021-12-03
Recruiting
Blueprint Medicines Corporation
Phase 2/3
534
Milan, Florence, Bologna, Catania, Pavia, Salerno, Verona, Vicenza
2021-11-30
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Aviano, Meldola, Milan, Parma, Ravenna, Roma, Verona
2021-11-17
Recruiting
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
DrugBezuclastinib
Cogent Biosciences, Inc.
Phase 2
140
Bologna, Florence, Salerno, Verona
2021-11-09
Active, closed
AstraZeneca
Phase 3
454
Milan, Monza, Orbassano, Parma, Roma, Verona
2021-10-28
Recruiting
Bayer
Phase 1/2
400
Aviano, Milan, Orbassano, Parma, Roma, Rozzano, Verona
2021-10-25
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Bologna, Milan, Reggio Emilia, Roma, Verona
2021-10-06
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Bologna, Milan, Roma, Verona
2021-09-13
Active, closed
AstraZeneca
Phase 3
98
Florence, Meldola, Messina, Naples, Padova, Roma, Terni, Verona
2021-09-12
Active, closed
Janssen Research & Development, LLC
Phase 4
411
Ancona, Monserrato, Reggio Emilia, Roma, Rozzano (MI), Verona
2021-08-30
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Naples, Milan, Siena, Bologna, Brescia, Verona
2021-08-12
Active, closed
Bristol-Myers Squibb
Phase 3
670
Genova, Pavia, Udine, Verona
2021-07-13
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
434
Bologna, Meldola, Milan, Pisa, Verona
2021-07-06
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Catania, Milan, Naples, Palermo, Rome, Torino, Verona
2021-06-17
Active, closed
Nobel Biocare
Observational
1,000
Cattolica, Verona
2021-05-26
Recruiting
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
NCT04503395Aortic Aneurysm, Abdominal
FCRE (Foundation for Cardiovascular Research and Education)
Not applicable
204
Bologna, Genova, Milan, Perugia, Turin, Verona
2021-05-21
Recruiting
Azienda Ospedaliera Universitaria Integrata Verona
Not applicable
900
Verona
2021-05-03
Recruiting
Ipsen
Phase 1/2
240
Brescia, Naples, Rome, Verona
2021-04-29
Active, closed
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsBispecific·Tagrisso·Osimertinib
Merus B.V.
Phase 1/2
194
Roma, Bologna, Brescia, Milan, Orbassano, Salerno, Verona
2021-04-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Milan, Pozzuoli, Orbassano, Verona, Ancona, Catania, Padova
2021-04-21
Active, closed
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Medtronic Cardiovascular
Not applicable
1,103
Bologna, Pisa, Verona
2021-04-02
Recruiting
Guerbet
Phase 4
2,076
Siena, Trieste, Milan, Roma, Verona
2021-03-24
Active, closed
Bristol-Myers Squibb
Phase 1/2
216
Bologna, Brescia, Florence, Verona
2021-03-22
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Aviano, Meldola, Milan, Pavia, Verona
2021-02-23
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Bologna, Florence, Meldola, Milan, Orbassano, Verona
2021-02-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Modena, Florence, Verona, Brescia, Milan, Padova, Roma
2020-12-08
Active, closed
Amgen
Phase 3
135
Florence, Milan, Pisa, Reggio Emilia, Torino, Verona
2020-12-04
Recruiting
Pancreatic Cancer Early Detection Consortium
NCT04970056Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Arbor Research Collaborative for Health
Observational
20,000
Verona
2020-09-18
Recruiting
Azienda Ospedaliera Universitaria Integrata Verona
Not applicable
216
Verona
2020-09-01
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
530
Milan, Naples, Pisa, Tortona, Verona
2020-06-29
Recruiting
International CIPN Assessment and Validation Study
NCT04633655Chemotherapy-induced Peripheral Neuropathy, Quality of Life
University of Milano Bicocca
Observational
1,000
Monza, Como, Genova, Messina, Padova, Verona
2020-06-08
Active, closed
AstraZeneca
Phase 2
452
Milan, Naples, Padova, Roma, Verona
2020-06-03
Active, closed
BeOne Medicines
Phase 1
437
Milan, Perugia, Ravenna, Roma, Verona
2020-03-24
Recruiting
Covid-19 in Hematological Malignancies
NCT04733729COVID-19 Infection in Hematological Malignancies Patients
Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
Observational
3,000
Brescia, Naples, Rome, Varese, Verona
2020-03-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Verona, Arezzo, Bari, Bologna, Milan, Modena, Padova, Pavia
2020-02-27
Active, closed
University of Roma La Sapienza
Observational
138
Padova, Roma, Verona
2019-12-20
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Sotorasib·Afatinib
Amgen
Phase 1
610
Milan, Pisa, Verona
2019-12-17
Active, closed
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Abiomed Inc.
Not applicable
527
Genoa, Milan, Verona, Rozzano
2019-12-12
Active, closed
Novo Nordisk A/S
Phase 3
134
Florence, Castelfranco Veneto, Milan, Udine, Verona
2019-10-21
Recruiting
Registry of Subjects at Risk of Pancreatic Cancer
NCT04095195Familial Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation, Lynch Syndrome
Associazione Italiana per lo Studio del Pancreas
Observational
1,000
Rozzano, Peschiera del Garda, Milan, Verona
2019-08-20
Active, closed
Novartis Pharmaceuticals
Phase 3
254
Genova, Milan, Verona, Naples
2019-07-26
Active, closed
AstraZeneca
Phase 3
908
Bologna, Milan, Naples, Roma, Tricase, Lecce, Verona
2019-04-29
Active, closed
AstraZeneca
Phase 3
810
Faenza, Florence, Milan, Naples, Roma, Verona
2019-04-16
Active, closed
Blueprint Medicines Corporation
Phase 2
251
Bologna, Milan, Salerno, Verona
2019-04-16
Active, closed
AbbVie
Phase 3
964
Modena, Ancona, Catania, Rome, Verona
2019-03-25
Active, closed
Azienda USL Reggio Emilia - IRCCS
Not applicable
10,156
Reggio Emilia, Milan, Verona
2019-03-01
Recruiting
Distribution of Lymph Node Metastases in Esophageal Carcinoma
NCT03222895Esophageal Neoplasms, Lymph Node Metastases
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Observational
5,000
Milan, Verona
2019-03-01
Active, closed
AstraZeneca
Phase 3
1,063
Bari, Bologna, Florence, Milan, Naples, Orbassano, Pozzuoli, Verona
2018-11-16
Active, closed
IRCCS San Raffaele
Observational
200
Lecco, Milan, Modena, Roma, Florence, Sassari, Verona
2018-10-30
Active, closed
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
NCT03569241Prostate Cancer, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic Cancer
University Hospital, Ghent
Phase 2
196
Milan, Naples, Pavia, Verona
2018-04-27
Recruiting
Effectiveness of a Home-Based Rehabilitation Program in Stroke Survivors Using the Euleria Home® Device
NCT06968923Stroke, Telemedicine, Rehabilitation, Telerehabilitation
Universita di Verona
Not applicable
90
Verona
2018-04-26
Active, closed
InSightec
Not applicable
92
Milan, Verona
2018-02-09
Recruiting
Prospective European Multicenter Study on Aortic Valve Replacement: (E-AVR Registry)
NCT03143361Aortic Valve Stenosis, Valve Heart Stenosis
University of Parma
Observational
8,000
Verona
2017-11-01
Active, closed
IRCCS San Raffaele
Observational
1,402
Milan, Padova, Verona
2017-01-01
Recruiting
Registry of Pancreatic Disease
NCT03807687Pancreatic Diseases, Pancreatic Neoplasms, Pancreatitis
Azienda Ospedaliera Universitaria Integrata Verona
Observational
3,000
Verona
2016-12-01
Active, closed
Eli Lilly and Company
Phase 1
223
Rozzano, Verona
2016-11-21
Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Observational
2,000
Milan, Padova, Verona
2016-09-01
Active, closed
Tesaro, Inc.
Phase 1
729
Milan, Modena, Naples, Roma, Verona
2016-03-07
Active, closed
AbbVie
Phase 3
1,629
Rozzano, Turin, Milan, Verona
2015-12-01
Recruiting
Patient Retrospective Outcomes (PRO)
NCT01550575Chronic Pain
Boston Scientific Corporation
Observational
15,000
Alessandria, Naples, Ravenna, Rionero in Vulture, Rome, Verona
2012-04-03
Rows per page Showing 1–277 of 277
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/verona

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 277 of those studies with a site in Verona.

How many clinical trials are recruiting in Verona?

151 of the 277 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 13 have not yet opened recruitment, 112 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Verona), 277 studies
PhaseStudiesRecruitingShare
Phase 3874031.4%
Not applicable432715.5%
Phase 2432015.5%
Observational422715.2%
Phase 1281510.1%
Phase 1/221167.6%
Phase 2/3852.9%
Phase 4511.8%

Most active sponsors

Lead sponsors with the most studies (Verona)
Lead sponsorStudiesRecruiting
Universita di Verona2015
Azienda Ospedaliera Universitaria Integrata Verona137
Amgen102
AstraZeneca101
Bristol-Myers Squibb105
Merck Sharp & Dohme LLC106
Novartis Pharmaceuticals104
Eli Lilly and Company95
Novo Nordisk A/S74
Incyte Corporation64
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.